scispace - formally typeset
N

Nir Polak

Researcher at Tel Aviv University

Publications -  7
Citations -  110

Nir Polak is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Internal medicine & Randomized controlled trial. The author has an hindex of 3, co-authored 4 publications receiving 30 citations.

Papers
More filters
Journal ArticleDOI

Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial.

TL;DR: It is indicated that HBOT may induce significant senolytic effects including significantly increasing telomere length and clearance of senescent cells in the aging populations.
Journal ArticleDOI

Hyperbaric oxygen therapy effects on pulmonary functions: a prospective cohort study

TL;DR: There was a modest non clinically significant though statistically significant improvement in PEF and FVC in the current cohort of patients who were without chronic lung diseases, and repeated hyperbaric oxygen exposure based on the currently used HBOT protocol is safe.
Journal ArticleDOI

Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial

TL;DR: In this paper , the effect of hyperbaric oxygen therapy (HBOT) on post-COVID-19 patients with ongoing symptoms for at least 3 months after confirmed infection was evaluated.
Journal ArticleDOI

Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial

TL;DR: Hyperbaric oxygen therapy was shown to induce cognitive enhancements in healthy aging adults via mechanisms involving regional changes in CBF, including attention, information processing speed and executive functions, which normally decline with aging.
Journal ArticleDOI

Hyperbaric oxygen therapy in children with post-concussion syndrome improves cognitive and behavioral function: a randomized controlled trial

TL;DR: In this article , the effect of hyperbaric oxygen therapy (HBOT) on children suffering from persistent post-concussion syndrome (PPCS) from mild-moderate TBI events six months to 10 years prior was evaluated.